Keros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept

MT Newswires Live2024-12-03

Keros Therapeutics (KROS) said Tuesday it has agreed to provide Takeda Pharmaceutical (TAK) with a global commercial license for elritercept, as well as to collaborate on the drug candidate's development.

Keros said it expects to receive an upfront payment of $200 million, with milestone payments that could reach up to $1.1 billion. It also expects to receive tiered royalties on net sales.

The upfront payment would extend Keros' operational runway through Q4 of 2028, the company said.

The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, Keros said.

Elritercept is currently in late-stage clinical trials for myelodysplastic syndrome and myelofibrosis, according to Keros.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488740911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488740911","market":"sh","top_or_hot":-1,"title":"Keros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept","media":"MT Newswires Live","content":"<html><body><p> Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KROS) said Tuesday it has agreed to provide Takeda Pharmaceutical (TAK) with a global commercial license for elritercept, as well as to collaborate on the drug candidate's development.</p><p>Keros said it expects to receive an upfront payment of $200 million, with milestone payments that could reach up to $1.1 billion. It also expects to receive tiered royalties on net sales.</p><p>The upfront payment would extend Keros' operational runway through Q4 of 2028, the company said.</p><p>The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, Keros said.</p><p>Elritercept is currently in late-stage clinical trials for myelodysplastic syndrome and myelofibrosis, according to Keros.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-03 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Keros Therapeutics (KROS) said Tuesday it has agreed to provide Takeda Pharmaceutical (TAK) with a global commercial license for elritercept, as well as to collaborate on the drug candidate's ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488740911","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488740911","pubTimestamp":1733230322,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Keros Therapeutics  said Tuesday it has agreed to provide Takeda Pharmaceutical  with a global commercial license for elritercept, as well as to collaborate on the drug candidate's development.Keros said it expects to receive an upfront payment of $200 million, with milestone payments that could reach up to $1.1 billion. It also expects to receive tiered royalties on net sales.The upfront payment would extend Keros' operational runway through Q4 of 2028, the company said.The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, Keros said.Elritercept is currently in late-stage clinical trials for myelodysplastic syndrome and myelofibrosis, according to Keros.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Keros Therapeutics与武田制药达成Elritercept全球开发和许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"KROS":0.9,"TAK":0.9},"content_text":"Keros Therapeutics (KROS) said Tuesday it has agreed to provide Takeda Pharmaceutical (TAK) with a global commercial license for elritercept, as well as to collaborate on the drug candidate's development.Keros said it expects to receive an upfront payment of $200 million, with milestone payments that could reach up to $1.1 billion. It also expects to receive tiered royalties on net sales.The upfront payment would extend Keros' operational runway through Q4 of 2028, the company said.The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, Keros said.Elritercept is currently in late-stage clinical trials for myelodysplastic syndrome and myelofibrosis, according to Keros.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488740911"}